Add To Watchlist
Share URL
About The Company
Description
Ilyang Pharmaceutical Co.
Read More
Overview
Value
49
Growth
35
Health
43
Management
2
Analyst Opinion
86
Total
43
All Scores Out Of 100
Best Features
- Has a low level of debt
- Price-to-earnings ratio of 12.9 is lower than the market average (19.6x)
- Has a margin-of-safety above fair value
- Liked by analysts
- Has strong dividend growth
- Low preportion of income is paid as dividend
Risk Factors
- Earnings have declined recently
- There is a history of diluting shareholders
- Does not hold enough liquid assets to cover short term liabilities
- Poor earnings and cashflow growth 0
Market Peers
007570.KS
Key Figures
PE Ratio (TTM)
12.93
Margin Of Safety (DCF)
83.22%
Revenue Growth (5 Year Average)
-0.20%
Ratings Consensus
Strong Buy
Share Buybacks
-0.01%
Dividend Yeild (TTM)
1.22%
Valuation
Value Score
49
- ✔ Price-to-earnings ratio of 12.9 is lower than the market average (19.6x)
- ✔ Margin-of-safety of 83.22% is better than the market average (17.95%)
- ✔ Estimated intrinsic-value of 32.61 Thousand KRW is higher than current price ( 17.95 Thousand KRW)
- ✘ Free-cashflow-yeild of 2.92% is worse than the market average (4.7%)
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: < 26919.2 KRW ✔
Current Price: 17800 KRW
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
12.93x
Free Cashflow Yeild
2.92%
PE/Earnings Growth
N/A
Price/Book
1.26x
Growth
Growth Score
35
- ✔ Revenue growth has improved this yeara
- ✔ 5 Year Average Cashflow growth of 24.73% is higher than the market average (12.35%)
- ✘ 5 Year Average Revenue growth of -0.20% is lower than the market average (10.97%)
- ✘ 5 Year Average Earnings growth of -8.21% is lower than the market average (14.48%)
- ✘ Earnings growth has slowed this year
- ✘ Free Cashflow growth has slowed this year
Revenue Growth
-0.20%
Earnings Growth
-8.21%
Cashflow Growth
24.73%
Health
Health Score
43
Altman Z Score
2.09
Piostroski Score
8.00
Debt/Equity
0.37x
Current Assets/Liabilities
0.66x
Free Cashflow/Total Debt
0.11x
Debt/Capital
0.67x
Management
Management Score
2
- ✔ Has issued new shares to finance growth when share price is high
- ✘ Return-on-capital-employed of 1.81% is lower than the market average (10%)
- ✘ Has a history of diluting shareholders to finance activity
- ✘ Has returned higher dividends when earnings have fallen
- ✘ Return-on-equity of 1.43% is lower than the market average (15%)
Average Buybacks/Dilution
-0.01%
Recent Buybacks/Dilution
-0.63%
5 Year Price Volitility
46.25%
Return On Assets
0.67%
Return On Capital Employed
1.81%
Return On Equity
1.43%
Return On Free Cashflow
-399.46%
Return On Investments
113.75%
Analysts
Analyst Opinion
86
- ✔ Ratings consensus is Strong Buy
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Ilyang Pharmaceutical Co.,Ltd
Currency
KRW
Beta
0.00895
Vol Avg
154841
Ceo
Cik
Cusip
Exchange
KSE
Full Time Employees
675
Industry
Drug Manufacturers—Specialty & Generic
Sector
Healthcare
Ipo Date
2000-01-04
Address
110, Hagal-ro
City
Yongin
State
Country
US
Zip
17096
Phone
82 3 1281 7851
All financial data provided by FMP